Business
Resverlogix to Collaborate with Cleveland Clinic
Planning for first small molecule ApoA-I IVUS study commences TSX Exchange Symbol: RVX SAN DIEGO,...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nPlanning for first small molecule ApoA-I IVUS study commences\n\n\nTSX Exchange Symbol: RVX\n\n\nSAN DIEGO, CA and CALGARY, AB, June 19 /CNW/ - Resverlogix Corp.\n("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce its\nsponsorship in a study which will address patients with acute coronary\nsyndrome. Dr. Stephen J. Nicholls, M.B.B.S. Ph.D. of the Cleveland Clinic\nCoordinating Center for Clinical Research will lead a team of experts\ncoordinating the development of a protocol for RVX-208 in a Phase 2b\nintravascular ultrasound study (IVUS). Resverlogix anticipates conducting the\n2b trial next year, upon completion of a successful Phase 1b/2a trial.\n\n\n"The IVUS Phase 2b study is a very exciting step for our lead drug\nRVX-208," said Donald J. McCaffrey, President & CEO of Resverlogix. "Our\nultimate goal is to demonstrate that RVX-208 can increase endogenous ApoA-I\nproduction in addition to atherosclerosis regression further supporting that\nRVX-208 could possibly regress the burden of atherosclerosis."\n\n\nCleveland Clinic researchers will assist in the planning and coordinating\nof the trial of RVX-208, a novel small molecule that enhances the production\nof ApoA-I and functional HDL. The study will seek to answer these important\nscientific questions by measuring the rate of regression of coronary disease\nusing intravascular ultrasound (IVUS), a technique that directly measures the\namount of plaque in the coronary arteries. Recent research has illustrated\nthat effecting the functionality of HDL and its main protein, ApoA-I, have\npromising potential to treat atherosclerosis, thereby reducing incidents of\ncardiovascular disease.\n\n\nAs a leader in ApoA-I technology Resverlogix, which has several internal\nApoA-I programs, has deemed it necessary to expand its clinical team. Thus\ntoday Resverlogix also announces the hiring of Dr. F. Allan Gordon, M.D.,\nPh.D. who will be the Company's Senior Vice President of Clinical Development.\nDr. Gordon has more than 20 years of experience as a research scientist and\nclinician in cardiology.\n\n\n"It is a pleasure to have an esteemed colleague such as Dr. Gordon join\nour team of experts," commented Dr. Jan Johansson, M.D., Ph.D., Senior Vice\nPresident Medical Affairs of Resverlogix. "Dr. Gordon'...